Decreasing glioma recurrence through adjuvant cancer stem cell inhibition.
Gliomas remain one of the most challenging solid organ tumors to treat and are marked clinically by invariable recurrence despite multimodal intervention (surgery, chemotherapy, radiation). This recurrence perhaps, is as a consequence of the failure to eradicate a tumor cell subpopulation, termed cancer stem cells. Isolating, characterizing, and understanding these tumor-initiating cells through cellular and molecular markers, along with genetic and epigenetic understanding will allow for selective targeting through therapeutic agents and holds promise for decreasing glioma recurrence.
Neman
Josh
J
Division of Neurosurgery, City of Hope National Cancer Center, Duarte, CA, USA.
Jandial
Rahul
R